Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Poking CD40 for cancer therapy, another example of the Goldilocks effect.

Drabick JJ, Schell TD.

Cancer Biol Ther. 2010 Nov 15;10(10):994-6. Epub 2010 Nov 15. No abstract available.

PMID:
21057206
2.

Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors.

Rüter J, Antonia SJ, Burris HA, Huhn RD, Vonderheide RH.

Cancer Biol Ther. 2010 Nov 15;10(10):983-93. doi: 10.4161/cbt.10.10.13251. Epub 2010 Nov 15.

3.

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O'Dwyer PJ, Running KL, Huhn RD, Antonia SJ.

J Clin Oncol. 2007 Mar 1;25(7):876-83.

PMID:
17327609
4.

Biology and clinical applications of CD40 in cancer treatment.

Fonsatti E, Maio M, Altomonte M, Hersey P.

Semin Oncol. 2010 Oct;37(5):517-23. doi: 10.1053/j.seminoncol.2010.09.002. Review.

PMID:
21074067
5.

The promise of monoclonal antibodies for the therapy of cancer.

Gutheil J.

Crit Rev Oncol Hematol. 2001 Apr;38(1):1-2. No abstract available.

PMID:
11255076
6.

American Association of Cancer Research Showcases Immunotherapy Advances.

Brower V.

J Natl Cancer Inst. 2015 Aug 4;107(8). pii: djv231. doi: 10.1093/jnci/djv231. Print 2015 Aug. No abstract available.

7.

Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.

Kornbluth RS, Stempniak M, Stone GW.

Int Rev Immunol. 2012 Aug;31(4):279-88. doi: 10.3109/08830185.2012.703272. Review.

8.

Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.

Richman LP, Vonderheide RH.

Cancer Immunol Res. 2014 Jan;2(1):19-26. doi: 10.1158/2326-6066.CIR-13-0152.

9.

Immunomodulatory antibody therapy of cancer: the closer, the better.

Dronca RS, Dong H.

Clin Cancer Res. 2015 Mar 1;21(5):944-6. doi: 10.1158/1078-0432.CCR-14-2111. Epub 2014 Oct 28.

10.

The use of agonistic anti-CD40 therapy in treatments for cancer.

Khong A, Nelson DJ, Nowak AK, Lake RA, Robinson BW.

Int Rev Immunol. 2012 Aug;31(4):246-66. doi: 10.3109/08830185.2012.698338. Review.

PMID:
22804570
11.

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.

Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH.

Science. 2011 Mar 25;331(6024):1612-6. doi: 10.1126/science.1198443.

12.

Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.

Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV.

Cancer Cell. 2016 Jun 13;29(6):820-831. doi: 10.1016/j.ccell.2016.05.001. Epub 2016 Jun 2.

13.

Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.

Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, Tötterman TH, Mangsbo SM.

Cancer Immunol Res. 2014 Jan;2(1):80-90. doi: 10.1158/2326-6066.CIR-13-0067. Epub 2013 Oct 21.

14.

Beyond ipilimumab: new approaches target the immunological synapse.

Garber K.

J Natl Cancer Inst. 2011 Jul 20;103(14):1079-82. doi: 10.1093/jnci/djr281. Epub 2011 Jul 7. No abstract available.

PMID:
21737695
15.

Agonistic CD40 antibodies and cancer therapy.

Vonderheide RH, Glennie MJ.

Clin Cancer Res. 2013 Mar 1;19(5):1035-43. doi: 10.1158/1078-0432.CCR-12-2064.

16.

Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.

Bajor DL, Xu X, Torigian DA, Mick R, Garcia LR, Richman LP, Desmarais C, Nathanson KL, Schuchter LM, Kalos M, Vonderheide RH.

Cancer Immunol Res. 2014 Nov;2(11):1051-8. doi: 10.1158/2326-6066.CIR-14-0154. Epub 2014 Sep 24.

17.
18.

Antibody therapy of cancer.

Scott AM, Wolchok JD, Old LJ.

Nat Rev Cancer. 2012 Mar 22;12(4):278-87. doi: 10.1038/nrc3236. Review.

PMID:
22437872
19.

CNTO-328 (Centocor).

Li J, Hu XF, Xing PX.

Curr Opin Investig Drugs. 2005 Jun;6(6):639-45. Review. No abstract available.

PMID:
15988916
20.

Harnessing immune responses in the tumor microenvironment: all signals needed.

Le DT, Jaffee EM.

Clin Cancer Res. 2013 Nov 15;19(22):6061-3. doi: 10.1158/1078-0432.CCR-13-2424. Epub 2013 Oct 4.

Supplemental Content

Support Center